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Abstract The transcriptional regulation of cardiovascular
development requires precise spatiotemporal control of
gene expression, and heterozygous mutations of transcrip-
tion factors have frequently been implicated in human
cardiovascular malformations. A novel mechanism
involving post-transcriptional regulation by small, non-
coding microRNAs (miRNAs) has emerged as a central
regulator of many cardiogenic processes. We are beginning
to understand the functions that miRNAs play during
essential biologic processes, such as cell proliferation,
differentiation, apoptosis, stress response, and tumorigen-
esis. The identiﬁcation of miRNAs expressed in speciﬁc
cardiac and vascular cell types has led to the discovery of
important regulatory roles for these small RNAs during
cardiomyocyte differentiation, cell cycle, conduction, and
vessel formation. Here, we overview the recent ﬁndings on
miRNA regulation in cardiovascular development. Further
analysis of miRNA function during cardiovascular devel-
opment will allow us to determine the potential for novel
miRNA-based therapeutic strategies.
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During the last decade, animal studies and advances in
human genetics have highlighted the need for precise reg-
ulation of key molecular pathways during embryonic
development. This is particularly true for the cardiovascular
system, in which haploinsufﬁciency typically causes human
disease [59]. The dosage of cardiogenic pathways can be
controlled at numerous levels, some of which have been
well studied. In particular, the transcriptional regulation of
cardiomyocyte differentiation and cardiac morphogenesis is
highly conserved across species, and heterozygous muta-
tions of transcription factors have frequently been impli-
cated in human cardiac malformations [46]. Recently, post-
transcriptional regulation by small noncoding RNAs, such
as microRNAs (miRNAs), has emerged as a central regu-
lator of many cardiogenic processes.
miRNAs are a large class of evolutionarily conserved,
small, noncoding RNAs, typically 20–26 nucleotides (nt) in
length, that primarily function post-transcriptionally by
interacting with the 30 untranslated region (UTR) of spe-
ciﬁc target mRNAs in a sequence-speciﬁc manner
(reviewed in Zhao and Srivastava [57]) The ﬁrst animal
miRNA was described in 1993 as a regulator of develop-
mental timing in Caenorhabditis elegans [27, 52], but it
was not until 2001 that miRNAs were recognized to be
widespread in all eukaryotes, including vertebrates [26, 37,
39]. More than 650 miRNAs are encoded in the human
genome, and each is assumed to target[100 mRNAs,
resulting in mRNA degradation or translational inhibition.
Interactions between miRNAs and mRNAs are thought to
require sequence homology in the 50 end of the miRNA;
however, signiﬁcant variance in the degree of comple-
mentation in the remaining sequence allows a single
miRNA to target a wide range of mRNAs, often regulating
multiple genes within a common pathway. As a result,
more than one third of mRNAs in the mammalian genome
are believed to be regulated by one or more miRNAs [8].
Despite advances in miRNA discovery, the role of
miRNAs in physiologic and pathophysiologic processes is
just emerging. It has become clear that miRNAs play
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cell proliferation, differentiation, apoptosis, stress
response, and tumorigenesis. Identiﬁcation of miRNAs
expressed in speciﬁc cardiac cell types has led to the dis-
covery of important regulatory roles for these small RNAs
during cardiomyocyte differentiation, cell cycle, and con-
duction, as well as during stages of cardiac hypertrophy in
adults, indicating that miRNAs may be as important as
transcription factors in controlling cardiac gene expression.
Here, we review the basic mechanisms by which miR-
NAs function, with a focus on the role of miRNAs during
development of the heart and vessels. It appears that a
network of miRNAs can be superimposed on well-descri-
bed signaling and transcriptional networks with consider-
able intersection between the two. Ultimately, knowledge
of the function and regulation of speciﬁc miRNAs and their
mRNA targets in the heart will lead to a deeper under-
standing of cardiac cell-fate decisions and morphogenesis
and ultimately could result in the development of novel
therapeutic or preventive approaches for heart disease.
miRNA Organization, Biogenesis, and Target
Recognition
miRNAs regulate gene expression at the post-transcrip-
tional level through mRNA degradation, translational
repression, or miRNA-mediated mRNA decay. Mature
miRNAs are formed in a multistep biologic process
involving critical endonucleases (Fig. 1). miRNAs are
initially transcribed from the genome into long (several
kilobases) 50 capped, polyadenylated (poly(A)) primary
transcripts (primiRNAs) by RNA polymerase II [7]. Some
miRNAs interspersed among repetitive DNA elements,
such as Alu repeats (50 AG/CT 30), can also be transcribed
by RNA polymerase III [5]. The miRNA-encoding portion
of the pri-miRNA forms a hairpin structure that is recog-
nized and cleaved in the nucleus by a microprocessing
complex. This complex consists of the double-stranded
RNA-speciﬁc nuclease DROSHA and its cofactor, Di-
George syndrome critical region 8 (DGCR8) [25]. The
resulting approximately 70-nt hairpin precursor miRNA
(pre-miRNA) is exported to the cytoplasm by the RAN-
GTP–dependent nuclear transport receptor, exportin-5,
which acts by recognizing a 2- to 3-base pair overhang of
the pre-miRNA stem-loop structure [4, 56]. A complex of
the RNAse III-like ribonuclease, Dicer, and the transacti-
vator RNA-binding protein then cleaves the pre-miRNA to
release the mature miRNA duplex.
An asymmetry in the relative thermodynamic stability of
the 50 ends of the miRNA duplex results in preferential
loading of the less stable approximately 22-nt strand into
the RNA-induced silencing complex (RISC); the other
strand is degraded, although in some cases both strands are
incorporated into the RISC [22, 40, 43]. The RISC helps
mediate miRNA–mRNA interactions and subsequent
mRNA repression or destabilization [19]. miRNAs typi-
cally bind to the 30 UTRs of their mRNA targets with
imprecise complementarity. Typically, the degree of Wat-
son–Crick base-pairing between bases 2 and 7 (the ‘‘seed
region’’) at the 50 end of the miRNA is critical for binding
mRNA targets [38, 48] and mediating repression. RISC-
bound miRNAs may also be sequestered away from
translational machinery in processing bodies, which act by
recruiting poly(A) nucleases to help modulate deadenyla-
tion of mRNA and thereby prevent translation [16, 23, 29].
miRNAs can be found in exons or introns of noncoding
transcripts with independent enhancer regulation and in the
introns and 30 UTRs of protein-coding transcripts. They can
also overlap with either an exon or an intron, depending on
the alternative splicing pattern. In ﬂies and worms, some
miRNAs in intronic regions bypass Drosha processing and
enter the miRNA biogenesis pathway as pre-miRNAs [41].
In many cases, miRNAs are clustered near other miRNAs,
and they are transcriptionally coregulated and share coop-
erative regulatory roles.
Several algorithmic databases have been designed for
miRNA target prediction that rely, for the most part, on the
following criteria: (1) conservation across species, (2)
complementarity of the 50 miRNA ‘‘seed match’’ to the 30
UTR (approximately 7 nt) [28, 38, 59], (3) G:U wobbles in
the seed [6], (4) the thermodynamic context of target
mRNA-binding sites (i.e., mRNA targets located in regions
of high free energy and unstable secondary structure are
favored) [58, 59], and (5) multiple miRNA-binding sites in
30 UTR [14]. These computational programs are continu-
ously updated to integrate new knowledge from validated
miRNA–mRNA interactions (reviewed in Sethupathy
[44]).
One approach that has showed the importance of miR-
NAs during vertebrate development has been to create
mutations in Dicer, the enzyme required to process miR-
NAs into their active form. Dicer is encoded by a single
locus in vertebrates. Zebraﬁsh lacking maternal and
endogenous Dicer die from defects in gastrulation, brain
morphogenesis, somitogenesis, and heart development [18,
51]. In mice, targeted deletion of Dicer causes lethality at
embryonic day 7.5 (E7.5), before body axis formation [2].
Cardiac-speciﬁc deletion of Dicer using Cre recombinase
expressed under the control of the endogenous Nkx2.5
regulatory elements resulted in embryonic lethality at
E12.5 [59]. The Nkx2.5-Cre is active from E8.5 during
heart patterning and differentiation but only after initial
commitment of cardiac progenitors [34]. It will be impor-
tant to determine whether Dicer is required for earlier steps
of cardiogenesis (before E8.5), such as cardiac lineage
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123speciﬁcation, because Dicer is required for embryonic stem
cell differentiation [21, 35]. Deletions of Dicer in speciﬁc
heart populations will show the importance of miRNA
function in distinct aspects of heart development.
Organization and Regulation of miR-1 and miR-133
Two widely conserved miRNAs that display cardiac mus-
cle- and skeletal muscle-speciﬁc expression during devel-
opment and in the adult human are miR-1 and miR-133a
(Fig. 2), which are derived from a common precursor
transcript (bicistronic) [9, 58]. Two highly conserved loci
encode the mature miR-1 (miR-1-1 and miR-1-2) and miR-
133a (miR-133a-1, miR-133a-2) transcripts, which appear
to be genetically redundant [24]. The mature forms of miR-
1 derived from the distinct loci are identical, as are the
miR-133a forms.
Cardiac transcription of miR-1/miR-133 bicistronic
precursors is directly regulated by myocyte enhancer
factor-2 (Mef2) and serum response factor (SRF) (Fig. 2a)
[58]. SRF binds to CArG motifs in promoters and
enhancers of muscle-speciﬁc genes that regulate hundreds
of miRNAs [36], although only a limited number have been
assigned target mRNAs. In the heart, SRF binds and acti-
vates the enhancer regions of miR-1/miR-133 in vitro and
in vivo through a serum-response element conserved from
ﬂy to human [58]. Concordant with their common cis- and
trans-regulation, both miR-1 and miR-133 are coexpressed
in cardiac and skeletal muscle throughout mouse devel-
opment (Fig. 2b) and are robustly expressed in the adult
human [9, 30, 58].
Function of miR-1 and miR-133a During Cardiogenesis
miR-1 expression is detectable by E8.5 in mouse and
increases throughout development. Overexpression of miR-
1 under the control of the b-MHC promoter diminishes the
pool of proliferating ventricular myocytes by inducing a
Fig. 1 Schematic
representation of miRNA
biogenesis and function.
Transcription of miRNA genes
is typically mediated by RNA
polymerase II (pol II) and can
be controlled by various
transcription factors (TF). The
initial transcripts, termed
‘‘primiRNAs,’’ can range from a
few hundred nucleotides to
several kilobases long. The
primiRNA has a characteristic
stem-loop structure that can be
recognized and cleaved by the
RNase III endonuclease Drosha,
along with its partner DGCR8
(DiGeorge syndrome critical
region 8 gene; also known as
Pasha). The cleavage product,
an approximately 70-nt stem-
loop pre-miRNA, is exported
from the nucleus by Exportin 5.
In the cytoplasm, another RNase
III enzyme, Dicer, further
cleaves the pre-miRNA into a
double-stranded mature miRNA
(approximately 21 nt), which is
incorporated into the RISC, thus
allowing preferential strand
separation of the mature
miRNA to repress mRNA
translation or destabilize mRNA
transcripts through cleavage or
deadenylation (adapted from
Zhao and Srivastava [57])
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123premature exit from the cell cycle. This negatively regulates
cardiac growth, in part by inhibiting translation of the heart
and neural crest derivative-2 protein, Hand2 [58], a basic
helix-loop-helix protein involved in ventricular myocyte
expansion. In mice, Hand2 is initially expressed throughout
the linear heart tube and then becomes restricted to the
developing atrial and ventricular myocardium with highest
expression in the right ventricle. Mice that lack Hand2 die at
E10.5 from right ventricular hypoplasia and decreased tra-
beculation in the left ventricle [47, 49, 55]. In mice over-
expressing miR-1, trabeculation is also decreased,
consistent with the Hand2 mutant phenotype, corroborating
Hand2 as a direct target of miR-1 [58]. Mice lacking miR-1
have an increase in Hand2 protein, providing yet further
evidence of Hand2 as a direct target of miR-1.
In Drosophila, miR-1 functions to pattern the dorsal
vessel (i.e., aorta/heart tube). Moreover, deletion of the
single miR-1 gene (dmiR-1) results in a muscle-differenti-
ation defect [24, 45]. In a subset of dmiR-1-null ﬂies,
muscle progenitors are arrested in a proliferative state and
accumulate ectopically. Drosophila hand does not seem to
be a target of miR-1 because the ﬂy hand ortholog lacks
miR-1-binding sites in its 30 UTR, suggesting that miRNA–
mRNA interactions may differ somewhat between species.
Instead, dmiR-1 targets transcripts encoding the Notch
ligand, Delta, which regulates the expansion of cardiac and
muscle progenitor cells [24], suggesting that miR-1 pro-
motes muscle differentiation through downregulation of
the Notch signaling pathway. This is consistent with the
known function of the Notch/Delta–signaling pathway
during developmental cell-fate decisions, including those
involving cardiac speciﬁcation [1].
In cultured myoblasts, miR-1 promotes myoblast differ-
entiation, whereas miR-133 stimulates myoblast prolifera-
tion [9]. Chen et al. showed in myoblast culture that miR-1
targets the histone deacetylase 4 (HDAC4) mRNA, a tran-
scriptional repressor of Mef2-dependent activation of mus-
cle-speciﬁc gene expression, suggesting that translational
repression of HDAC4 by miR-1 enhances gene activation of
Mef2-dependent promoters. They also showed that miR-133
targets SRF, which is important in muscle proliferation,
differentiation, and activation of the miR-1/miR-133 tran-
script, thus creating a negative-feedback regulatory loop
(Fig. 2c). When rat ventricular cells are subjected to oxi-
dative stress, miR-1 and miR-133 have opposing effects on
apoptosis: miR-1 targets the anti-apoptotic heat-shock pro-
teins HSP60 and HSP70 and is apoptotic, whereas miR-133
represses caspase-9, a regulator of mitochondria-mediated
apoptosis [54], and is anti-apoptotic.
Targeted deletion in mice will be invaluable for investi-
gating the functional role of individual miRNAs. Surpris-
ingly, disruption of just one of the two miR-1 family
members, miR-1-2, results in a range of abnormalities,
includingcell-cycledysregulation,heartmalformations,and
postnatal electrophysiological defects. Heterozygous miR-
1-2-null mice survive to reproduce, but 50% of miR-1-2
homozygous null mice die between E15.5 and birth from
ventricular septal defects and cardiac dysfunction. These
defects can occur from dysregulation of a multitude of
events during cardiogenesis, and it is likely that miR-1-2
regulates numerous genes during this process. Precise dos-
age of Hand2 is crucial for normal cardiomyocyte prolifer-
ation and development, and increased levels of Hand2 may
contribute to the ventricular septal defects (Fig. 2c) [59].
miR-1-2-null mice that survive until birth often die sud-
denly [59]. Electrophysiologic testing showed a spectrum of
cardiac arrhythmiasinmutant mice,whichmaybecausedin
part by increased levels of the transcription factor Iroquois
homeobox 5 (Irx5). Irx5 regulates the cardiac ventricular
repolarization gradient by negatively regulating the
Fig. 2 Summary of miR-1 and miR-133 genomic organization,
regulation, and expression during mouse cardiogenesis. a Chromo-
somal locations of mouse miR-1 and miR-133a. The miR-1/133a
clusters are transcribed as bicistronic transcripts. b LacZ directed by
an upstream enhancer of the miR-1-2/miR-133a-2 and miR-1-1 miR-
133a-1 clusters, respectively, shows expression in the heart (ht) and
somites (arrowhead) at mouse embryonic day 11.5. c Cardiac
expression of miR-1 and miR-133 is regulated by SRF. Targets of
miR-1 and miR-133 in cardiac muscle are shown
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123expression of potassium channel genes, such as Kcnd2 [13].
The 30 UTR of Irx5 contains a well-conserved miR-1–bind-
ing site and is a direct target of miR-1 (Fig. 2c) [59]. In the
miR-1-2–null hearts, Irx5 transcripts were upregulated, and
its target gene, Kcnd2, was correspondingly downregulated.
Postnatal mouse cardiomyocytes terminally exit the cell
cycle after the ﬁrst 10 days of life. However, miR-1-2–null
adultmicehaveanincreaseinmitoticcardiacmyocytesalong
with cardiac hyperplasia. These abnormalities could reﬂect
the effect of miR-1 on Notch signaling and the derepression
of Hand2 (Fig. 2c), which promotes myocyte expansion. In
addition, genome-wide proﬁling of miR-1-2 mutant adult
mouse hearts suggests a broad upregulation of positive reg-
ulators of the cell cycle and downregulation of tumor sup-
pressors, indicating a shift in the ‘‘threshold’’ of cells to re-
enter the cell cycle [59]. Whether this change promotes car-
diac repair after injury remains to be determined.
Similarly, targeted deletion of miR-133a in mice has
helped to elucidate its role during cardiac development
[31]. Unlike miR-1, single mutations of either miR-133a-1
or miR-133a-2 caused no overt phenotype. However,
combined deletion of both miRNAs led to partially pene-
trant ventricular septal defects and decreased survival at
birth. Adult compound mutant mice developed dilated
cardiomyopathy and lethal heart failure. miR-133a was
found to suppress smooth-muscle gene expression and
cardiomyocyte proliferation, in part by way of repression
of SRF and cyclin D2 (Fig. 2c).
During early cell fate decisions of mouse and human
embryonic stem (ES) cells, miR-1, and miR-133 are
expressed just as mesoderm emerges and function in con-
cert to promote mesoderm induction while suppressing
differentiation into the ectodermal or endodermal lineages
(Fig. 3)[ 20]. However, miR-1 and miR-133 have antago-
nistic effects on further adoption of muscle lineages: miR-1
promotes differentiation of mouse and human ES cells
toward a cardiac fate, whereas miR-133 inhibits differen-
tiation into cardiac muscle. miR-1 appears to exert this
effect, in part, by translationally repressing the mammalian
orthologue of delta, Delta-like-1 (Dll-1), similar to the
repression seen in the ﬂy (Fig. 2c) [20]. Thus, the bicis-
tronic miR-1/miR-133 transcript encodes distinct mature
miRNAs that likely share common targets yet complement
each other by balancing the differentiation and prolifera-
tion of cardiac and skeletal muscle lineages.
miR-143/145 Regulate Smooth-Muscle Plasticity
Vascular smooth muscle cells have the unique capacity to
oscillate between a contractile phenotype and a less dif-
ferentiated, more synthetic state in response to external
queues. This phenotypic modulation is a major component
of the vascular repair process and certain diseases, such as
atherosclerosis. Not surprisingly, it involves dramatic
changes in the smooth-muscle gene program, which are
heavily inﬂuenced by particular miRNAs.
Among the most highly enriched microRNAs in the
vascular smooth muscle are miR-143 and miR-145. These
two microRNAs are cotranscribed from a single locus
under the transcriptional control of SRF, myocardin, and
Nkx2.5 [12]. Interestingly, their expression is strongly
downregulated in injured or atherosclerotic vessels, which
are comprised of synthetic smooth muscle cells [10, 12, 15,
53]. Indeed, miR-143 and miR-145 target a network of
transcription factors, including Klf4, Klf5, myocardin,
Fig. 3 Model of miR-1/miR-
133 effects during embryonic
stem-cell differentiation. miR-1
and miR-133 promote
differentiation of mesoderm and
inhibit endoderm and ectoderm
differentiation at speciﬁc stages
as indicated and have opposing
effects in later steps of muscle
differentiation. miR-1 inhibition
of Dll-1 translation, along with
yet unknown targets, likely
contribute to the observed
effects of miR-1 (from Ivey
et al. [20])
Pediatr Cardiol (2010) 31:349–356 353
123MRTFB, and Elk-1, which is consistent with a role for
these miRNAs in regulating the quiescent versus prolifer-
ative phenotype of smooth muscle (Fig. 4)[ 12, 53]. Fur-
ther, targeted deletion of these miRNAs in mice showed
their importance in achieving vascular tone and responding
to vascular injury [3, 15, 53] and led to the identiﬁcation of
the angiotensin-converting enzyme as a target of miR-145
[3]. miR-145 was also found to be necessary for smooth-
muscle conversion from ﬁbroblasts and sufﬁcient to dif-
ferentiate smooth muscle cells from multipotent neural
crest stem cells, further implicating microRNAs as regu-
lators of cell-fate decisions [12]. Similarly, miR-221 and
miR-222 regulate smooth-muscle cell proliferation and
modulate the deleterious vascular response after angio-
plasty [32]. Therefore, these miRNAs represent potential
targets for the diagnosis and therapy of vascular disease.
miR-138 Regulation of Cardiac Patterning
Intricate transcriptional networks establish chamber-spe-
ciﬁc gene expression, and these patterning events are
highly conserved across species, from zebraﬁsh to human
[46]. Zebraﬁsh are useful models to study cardiac pat-
terning events because of their simple two-chambered
heart, which consists of a single atrium and ventricle sep-
arated by the atrioventricular canal (AVC). The atrial and
ventricular chambers express unique myosin genes,
whereas the AVC expresses distinct genes, such as cspg2,
encoding versican, notch1b, and tbx2 [11, 42]. miR-138 is
a highly conserved miRNA found in many parts of the
embryo, but within the zebraﬁsh heart it is speciﬁcally
expressed in the ventricular chamber [33]. Disruption of
miR-138 function led to expansion of AVC gene expres-
sion into the ventricle and failure of ventricular
cardiomyoctyes to fully mature. miR-138 normally restricts
AVC gene expression by directly repressing cspg2 in the
ventricle. This event is reinforced by ventricular repression
of retinoic acid dehydrogenase, resulting in decreased ret-
inoic acid, which is a positive regulator of cspg2 [33]. It is
likely that other region-speciﬁc miRNAs will reinforce
known signaling and transcriptional networks that establish
patterns of gene expression throughout the developing
heart tube.
miR-126 Regulation of Angiogenesis
In addition to miRNA regulation of cardiomyocytes and
smooth muscle, two recent reports regarding the endothe-
lial-speciﬁc miRNA, miR-126, illustrate what will likely be
a broader function of tissue-speciﬁc miRNAs during car-
diovascular development [17, 50]. miR-126, which is
located in the intron of an endothelial-speciﬁc gene, Egﬂ7,
regulates endothelial cell migration and integrity of capil-
lary tubes in vitro [17]. In zebraﬁsh embryos, miR-126 was
similarly required for vascular integrity with vascular col-
lapse and extensive hemorrhage observed on disruption of
miR-126 function [17]. This function was conserved in
mice, in which targeted deletion of miR-126 resulted in
cranial hemorrhages and defects in angiogenesis [50]. miR-
126 appears to function in part to promote vascular endo-
thelial growth factor (VEGF) signaling by directly target-
ing multiple repressors of VEGF signaling, including
Spred1 [17, 50] and Pik3r2 [17]. Mice lacking miR-126
had an impaired ability to generate new blood vessels in
response to cardiac injury. Thus, miR-126-mediated regu-
lation of angiogenesis may be a valuable therapeutic target
to promote new blood vessel formation in ischemic con-
ditions as well to inhibit angiogenesis during tumor growth.
Fig. 4 miR-143 and miR-145
are transcriptionally regulated
by SRF and repress multiple
factors that normally promote
the synthetic smooth-muscle
phenotype (lavender). These
include Klf4, which interacts
with SRF and also represses
Myocd. miR-145 has a positive
effect on Myocd activity to
concurrently promote the
contractile smooth-muscle
phenotype (peach), thereby also
reinforcing miR-145 and miR-
143 expression (from Cordes
et al. [12])
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The function of miRNAs in cardiovascular development
reviewed here likely foreshadows a much broader role of
dozens of miRNAs in regulating most aspects of cardio-
vascular development. Through their ability to post-trans-
criptionally regulate mRNA levels, and thus manage
protein dosage, miRNAs provide ﬁner regulation within the
complex molecular networks that regulate cardiogenesis.
The importance of this ﬁne regulation is highlighted by the
recognition that most known genetic causes of heart mal-
formations in humans result from haploinsufﬁciency or
heterozygous point mutations. The ﬁeld of miRNA biology
is growing rapidly, and new tools and mechanisms are
becoming available. A critical hurdle will be to efﬁciently
identify direct miRNA targets and to integrate cardiovas-
cular enriched targets with previously described regulatory
networks. With further characterization, elucidating the
function of cardiac-enriched miRNAs may provide us with
new diagnostic, prognostic, and therapeutic targets for
many forms of cardiovascular disease.
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